Immunological aspects of experimental brain tumors (review).

Evidence that experimental neural tumors contain glia specific and glioma-associated antigens is reviewed. The fact that glioma cells share antigens with normal glia cells is of crucial importance for the histogenetic immunodiagnosis of intracranial neoplasms. Moreover, the increasing use of in vitro techniques in neuro-oncology has accentuated the necessity for employment of cell-type characteristic antigens. This allows for objective identification of the various types of brain tumor cells, and also for ascertaining the neurological nature of long-term cultured cells. Humoral and cell-mediated immune reactions to gliomas could be demonstrated in autochthonous and syngeneic hosts. Since glioma-associated antigens are rather weak and glioma cells are low immunogens, various approaches for enhancing glioma-cell immunogenicity have been described, such as treatment with membrane-modifying enzymes, or haptenization with various chemicals. Recently, nitrophenylation of glioma cells has become available for artificially increasing the immunogenicity of these cells. Furthermore, methods have recently been worked out by which monoclonal antibodies of predefined specificity can be produced in order to analyze the nature of glioma-associated antigens. Such methods may have a significant impact on clinical immunodiagnostics, and perhaps on the development of new immunotherapeutic approaches.